Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

Dominique Rosillon; Laurence Baril; Maria Rowena Del Rosario-Raymundo; Cosette Marie Wheeler; Susan Rachel Skinner; Suzanne Marie Garland; Jorge Salmeron; Eduardo Lazcano-Ponce; Carlos Santiago Vallejos; Tanya Stoney; Bram ter Harmsel; Timothy Yong Kuei Lim; Swee Chong Quek; Galina Minkina; Shelly Ann McNeil; Celine Bouchard; Kah Leng Fong; Deborah Money; Arunachalam Ilancheran; Alevtina Savicheva; Margaret Cruickshank; Archana Chatterjee; Alison Fiander; Mark Martens; Marie Cecile Bozonnat; Frank Struyf; Gary Dubin; Xavier Castellsagué

doi:10.1002/cam4.1879

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

Dominique Rosillon (Corresponding Author), Laurence Baril, Maria Rowena Del Rosario-Raymundo, Cosette Marie Wheeler, Susan Rachel Skinner, Suzanne Marie Garland, Jorge Salmeron, Eduardo Lazcano-Ponce, Carlos Santiago Vallejos, Tanya Stoney, Bram ter Harmsel, Timothy Yong Kuei Lim, Swee Chong Quek, Galina Minkina, Shelly Ann McNeil, Celine Bouchard, Kah Leng Fong, Deborah Money, Arunachalam Ilancheran, Alevtina SavichevaMargaret Cruickshank, Archana Chatterjee, Alison Fiander, Mark Martens, Marie Cecile Bozonnat, Frank Struyf, Gary Dubin, Xavier Castellsagué

Medical Education

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

12 Downloads (Pure)

Abstract

Abstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. Results Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+). Conclusions Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.

Original language	English
Pages (from-to)	4938-4953
Number of pages	15
Journal	Cancer Medicine
Volume	8
Issue number	10
Early online date	5 Jul 2019
DOIs	https://doi.org/10.1002/cam4.1879
Publication status	Published - Aug 2019

Bibliographical note

Funder: GlaxoSmithKline Biologicals SA

Keywords

human papillomavirus infection
naturally acquired antibodies
redetection or reactivation of HPV infection
cervical abnormality
risk reduction
IMMUNITY
EFFICACY
SUBSEQUENT HPV INFECTION
OLDER
FOLLOW-UP
SERUM ANTIBODIES
CONTROL ARM
DOUBLE-BLIND
HUMAN-PAPILLOMAVIRUS INFECTION
16/18 AS04-ADJUVANTED VACCINE

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cam4.1879Licence: CC BY

Rossilon_etal_cam_risk_of_newly-VOR
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/
Final published version, 867 KBLicence: CC BY

Cite this

Rosillon, D., Baril, L., Del Rosario-Raymundo, M. R., Wheeler, C. M., Skinner, S. R., Garland, S. M., Salmeron, J., Lazcano-Ponce, E., Vallejos, C. S., Stoney, T., ter Harmsel, B., Lim, T. Y. K., Quek, S. C., Minkina, G., McNeil, S. A., Bouchard, C., Fong, K. L., Money, D., Ilancheran, A., ... Castellsagué, X. (2019). Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies. Cancer Medicine, 8(10), 4938-4953. https://doi.org/10.1002/cam4.1879

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies. / Rosillon, Dominique (Corresponding Author); Baril, Laurence; Del Rosario-Raymundo, Maria Rowena et al.
In: Cancer Medicine, Vol. 8, No. 10, 08.2019, p. 4938-4953.

Research output: Contribution to journal › Article › peer-review

Rosillon, D, Baril, L, Del Rosario-Raymundo, MR, Wheeler, CM, Skinner, SR, Garland, SM, Salmeron, J, Lazcano-Ponce, E, Vallejos, CS, Stoney, T, ter Harmsel, B, Lim, TYK, Quek, SC, Minkina, G, McNeil, SA, Bouchard, C, Fong, KL, Money, D, Ilancheran, A, Savicheva, A, Cruickshank, M, Chatterjee, A, Fiander, A, Martens, M, Bozonnat, MC, Struyf, F, Dubin, G & Castellsagué, X 2019, 'Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies', Cancer Medicine, vol. 8, no. 10, pp. 4938-4953. https://doi.org/10.1002/cam4.1879

@article{857547c6156444b9a6a1de26d811fd7d,

title = "Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies",

abstract = "Abstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. Results Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+). Conclusions Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.",

keywords = "human papillomavirus infection, naturally acquired antibodies, redetection or reactivation of HPV infection, cervical abnormality, risk reduction, IMMUNITY, EFFICACY, SUBSEQUENT HPV INFECTION, OLDER, FOLLOW-UP, SERUM ANTIBODIES, CONTROL ARM, DOUBLE-BLIND, HUMAN-PAPILLOMAVIRUS INFECTION, 16/18 AS04-ADJUVANTED VACCINE",

author = "Dominique Rosillon and Laurence Baril and {Del Rosario-Raymundo}, {Maria Rowena} and Wheeler, {Cosette Marie} and Skinner, {Susan Rachel} and Garland, {Suzanne Marie} and Jorge Salmeron and Eduardo Lazcano-Ponce and Vallejos, {Carlos Santiago} and Tanya Stoney and {ter Harmsel}, Bram and Lim, {Timothy Yong Kuei} and Quek, {Swee Chong} and Galina Minkina and McNeil, {Shelly Ann} and Celine Bouchard and Fong, {Kah Leng} and Deborah Money and Arunachalam Ilancheran and Alevtina Savicheva and Margaret Cruickshank and Archana Chatterjee and Alison Fiander and Mark Martens and Bozonnat, {Marie Cecile} and Frank Struyf and Gary Dubin and Xavier Castellsagu{\'e}",

note = "Funder: GlaxoSmithKline Biologicals SA ",

year = "2019",

month = aug,

doi = "10.1002/cam4.1879",

language = "English",

volume = "8",

pages = "4938--4953",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "Wiley",

number = "10",

}

TY - JOUR

T1 - Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

AU - Rosillon, Dominique

AU - Baril, Laurence

AU - Del Rosario-Raymundo, Maria Rowena

AU - Wheeler, Cosette Marie

AU - Skinner, Susan Rachel

AU - Garland, Suzanne Marie

AU - Salmeron, Jorge

AU - Lazcano-Ponce, Eduardo

AU - Vallejos, Carlos Santiago

AU - Stoney, Tanya

AU - ter Harmsel, Bram

AU - Lim, Timothy Yong Kuei

AU - Quek, Swee Chong

AU - Minkina, Galina

AU - McNeil, Shelly Ann

AU - Bouchard, Celine

AU - Fong, Kah Leng

AU - Money, Deborah

AU - Ilancheran, Arunachalam

AU - Savicheva, Alevtina

AU - Cruickshank, Margaret

AU - Chatterjee, Archana

AU - Fiander, Alison

AU - Martens, Mark

AU - Bozonnat, Marie Cecile

AU - Struyf, Frank

AU - Dubin, Gary

AU - Castellsagué, Xavier

N1 - Funder: GlaxoSmithKline Biologicals SA

PY - 2019/8

Y1 - 2019/8

N2 - Abstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. Results Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+). Conclusions Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.

AB - Abstract Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti-HPV antibodies is uncertain. We examined the risk of HPV infections as defined by HPV DNA detection and cervical abnormalities among women >25 years in the Human Papilloma VIrus Vaccine Immunogenicity ANd Efficacy trial's (VIVIANE, NCT00294047) control arm. Methods Serum anti-HPV-16/18 antibodies were determined at baseline and every 12 months in baseline DNA-negative women (N = 2687 for HPV-16 and 2705 for HPV-18) by enzyme-linked immunosorbent assay (ELISA) from blood samples. HPV infections were identified by polymerase chain reaction (PCR) every 6-months, and cervical abnormalities were confirmed by cytology every 12 months. Data were collected over a 7-year period. The association between the risk of type-specific infection and cervical abnormalities and serostatus was assessed using Cox proportional hazard models. Results Risk of newly detected HPV-16-associated 6-month persistent infections (PI) (hazard ratio [HR] = 0.56 [95%CI:0.32; 0.99]) and atypical squamous cells of undetermined significance (ASC-US+) (HR = 0.28 [0.12; 0.67]) were significantly lower in baseline seropositive vs baseline seronegative women. HPV-16-associated incident infections (HR = 0.81 [0.56; 1.16]) and 12-month PI (HR = 0.53 [0.24; 1.16]) showed the same trend. A similar trend of lower risk was observed in HPV-18-seropositive vs -seronegative women (HR = 0.95 [0.59; 1.51] for IIs, HR = 0.43 [0.16; 1.13] for 6-month PIs, HR = 0.31 [0.07; 1.36] for 12-month PIs, and HR = 0.61 [0.23; 1.61] for ASC-US+). Conclusions Naturally acquired anti-HPV-16 antibodies were associated with a decreased risk of subsequent infection and cervical abnormalities in women >25 years. This possible protection was lower than that previously reported in 15- to 25-year-old women.

KW - human papillomavirus infection

KW - naturally acquired antibodies

KW - redetection or reactivation of HPV infection

KW - cervical abnormality

KW - risk reduction

KW - IMMUNITY

KW - EFFICACY

KW - SUBSEQUENT HPV INFECTION

KW - OLDER

KW - FOLLOW-UP

KW - SERUM ANTIBODIES

KW - CONTROL ARM

KW - DOUBLE-BLIND

KW - HUMAN-PAPILLOMAVIRUS INFECTION

KW - 16/18 AS04-ADJUVANTED VACCINE

UR - http://www.scopus.com/inward/record.url?scp=85068511762&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/risk-newly-detected-infections-cervical-abnormalities-adult-women-seropositive-seronegative-naturall

U2 - 10.1002/cam4.1879

DO - 10.1002/cam4.1879

M3 - Article

SN - 2045-7634

VL - 8

SP - 4938

EP - 4953

JO - Cancer Medicine

JF - Cancer Medicine

IS - 10

ER -

Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this